dose combination antiretroviral medication formulated for the effective management of Human Immunodeficiency Virus type 1 (HIV-1) infection. Manufactured by Kureasia Pharma, this triple combination tablet provides a comprehensive and potent therapeutic approach that simplifies treatment regimens, enhances adherence, and supports sustained viral suppression in patients requiring lifelong HIV therapy. The formulation combines three active agents with complementary mechanisms of action to target multiple stages of the HIV replication cycle, thereby ensuring optimal viral control and minimizing the risk of resistance development.
Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome, a crucial step in the viral replication process. This inhibition prevents the establishment of infection in new cells and helps maintain long-term suppression of viral load. Tenofovir Disoproxil Fumarate (TDF) and Lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that act by interfering with the reverse transcription of viral RNA into DNA. By inhibiting the reverse transcriptase enzyme, these agents effectively prevent the formation of viral DNA, stopping replication and reducing the amount of virus in the body. When combined, Dolutegravir, Tenofovir, and Lamivudine deliver a synergistic antiretroviral effect with a high genetic barrier to resistance and excellent tolerability.
This fixed-dose combination is recommended for the treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg. It is commonly used as part of first-line therapy in accordance with global HIV treatment guidelines, offering the advantages of once-daily dosing and minimal drug-drug interactions. The combination provides effective viral suppression, immune restoration, and long-term clinical stability, making it a preferred regimen in both treatment-naïve and certain treatment-experienced patients.
The tablet is typically administered orally once daily, with or without food, as directed by a healthcare professional. Adherence to daily dosing is essential for maintaining consistent plasma concentrations and achieving sustained viral suppression. The combination is generally well tolerated, with the most common side effects being mild headache, nausea, fatigue, and occasional gastrointestinal discomfort. Rare adverse events may include elevations in liver enzymes or renal function parameters, which should be monitored periodically during therapy.
Kureasia Pharma ensures that each tablet is manufactured under stringent Good Manufacturing Practices (GMP) and international quality standards, guaranteeing product purity, efficacy, and safety. The tablets are supplied in moisture-resistant packaging to preserve stability and shelf life. Proper storage below 30°C, away from moisture and sunlight, is recommended.
By integrating the proven efficacy of Dolutegravir, Tenofovir Disoproxil Fumarate, and Lamivudine in a single, convenient formulation, Kureasia Pharma delivers a reliable, patient-friendly solution that enhances compliance and therapeutic success. This fixed-dose combination represents an essential advancement in antiretroviral therapy, designed to suppress viral replication, reduce disease progression, and improve the quality of life for individuals living with HIV